133 related articles for article (PubMed ID: 12012106)
1. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression.
Prins RM; Scott GP; Merchant RE; Graf MR
Cancer Immunol Immunother; 2002 Jun; 51(4):190-9. PubMed ID: 12012106
[TBL] [Abstract][Full Text] [Related]
2. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.
Graf MR; Prins RM; Hawkins WT; Merchant RE
Cancer Immunol Immunother; 2002 Jun; 51(4):179-89. PubMed ID: 12012105
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas.
Graf MR; Sauer JT; Merchant RE
J Neurooncol; 2005 May; 73(1):29-36. PubMed ID: 15933813
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma.
Jeffes EW; Zhang JG; Hoa N; Petkar A; Delgado C; Chong S; Obenaus A; Sanchez R; Khalaghizadeh S; Khomenko T; Knight BA; Alipanah R; Nguyen TV; Shah C; Vohra S; Zhuang JL; Liu J; Wepsic HT; Jadus MR
J Immunol; 2005 Mar; 174(5):2533-43. PubMed ID: 15728459
[TBL] [Abstract][Full Text] [Related]
5. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model.
Jia W; Jackson-Cook C; Graf MR
J Neuroimmunol; 2010 Jun; 223(1-2):20-30. PubMed ID: 20452681
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
8. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis.
Prins RM; Graf MR; Merchant RE
Cancer Immunol Immunother; 2001 Aug; 50(6):285-92. PubMed ID: 11570581
[TBL] [Abstract][Full Text] [Related]
10. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
11. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity.
Graf MR; Prins RM; Merchant RE
J Immunol; 2001 Jan; 166(1):121-9. PubMed ID: 11123284
[TBL] [Abstract][Full Text] [Related]
12. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
13. T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas.
Sanchez R; Williams C; Daza JL; Dan Q; Xu Q; Chen Y; Delgado C; Arpajirakul N; Jeffes EW; Kim RC; Douglass T; Al Atar U; Terry Wepsic H; Jadus MR
Cell Immunol; 2002 Jan; 215(1):1-11. PubMed ID: 12142031
[TBL] [Abstract][Full Text] [Related]
14. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery.
Graf MR; Prins RM; Poulsen GA; Merchant RE
J Neuroimmunol; 2003 Jul; 140(1-2):49-60. PubMed ID: 12864971
[TBL] [Abstract][Full Text] [Related]
15. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
16. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
Herrlinger U; Kramm CM; Johnston KM; Louis DN; Finkelstein D; Reznikoff G; Dranoff G; Breakefield XO; Yu JS
Cancer Gene Ther; 1997; 4(6):345-52. PubMed ID: 9408604
[TBL] [Abstract][Full Text] [Related]
17. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.
Chen JC; Chen Y; Wu JM; Su YH; Tai KF; Tseng SH
Cancer Immunol Immunother; 2006 Jul; 55(7):873-83. PubMed ID: 16133106
[TBL] [Abstract][Full Text] [Related]
18. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
19. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.
Liau LM; Black KL; Prins RM; Sykes SN; DiPatre PL; Cloughesy TF; Becker DP; Bronstein JM
J Neurosurg; 1999 Jun; 90(6):1115-24. PubMed ID: 10350260
[TBL] [Abstract][Full Text] [Related]
20. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors.
Chang CJ; Tai KF; Roffler S; Hwang LH
J Immunol; 2004 Nov; 173(10):6025-32. PubMed ID: 15528337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
